Taking Semaglutide Helps Teens Lose Weight and Improve Heart Health

Teenage weight problems is a severe well being concern that may have long-term penalties for each bodily and psychological well-being. Causes of teenage weight problems can embrace genetics, unhealthy consuming habits, and lack of bodily exercise. It can result in quite a lot of well being points akin to sort 2 diabetes, coronary heart illness, and hypertension.A brand new research revealed within the New England Journal of Medicine and introduced at Obesity Week 2022 has discovered that the drug semaglutide is efficient in serving to adolescents who’re overweight or obese drop pounds and enhance their cardiovascular well being.In a global section 3a scientific trial, adolescents who took semaglutide as soon as every week skilled a 16.1% lower of their physique mass index (BMI), whereas those that took a placebo noticed a rise of 0.6% of their BMI. Semaglutide is already accredited to be used in adults with weight problems or obese.“Rates of weight problems are growing, not simply within the U.S., however everywhere in the world,” stated senior writer Silva Arslanian, M.D., professor of pediatrics and scientific and translational science and who holds the Richard L. Day Endowed Chair in Pediatrics on the University of Pittsburgh School of Medicine. “Typically, we make life-style suggestions: Eat extra greens; don’t eat fried meals; don’t drink soda. But sadly, we stay in a really obesogenic setting, so it may be very exhausting to make these adjustments. There is an actual want for secure and efficient drugs to deal with weight problems.”Semaglutide is an weight problems drug that mimics a hormone referred to as glucagon-like peptide-1 to focus on areas of the mind that lower urge for food and enhance management of consuming. In 2021, this drug was accredited for power weight administration in adults with weight problems or obese.To assess whether or not semaglutide can be efficient in youths, researchers enrolled 201 adolescents aged between 12 and 18 years with weight problems or obese throughout a number of facilities. Participants obtained both once-weekly subcutaneous injections of semaglutide 2.4 mg or placebo, and all obtained concurrent life-style intervention — counseling on wholesome vitamin and bodily exercise — all through the trial.After 68 weeks, 72.5% of semaglutide contributors had achieved at the least 5% weight reduction in comparison with simply 17% of these on placebo.“The outcomes are wonderful,” stated Arslanian, who can be director of the Pediatric Clinical and Translational Research Center and scientific director of the Center for Pediatric Research in Obesity and Metabolism at Pitt and UPMC Children’s Hospital of Pittsburgh. “For an individual who’s 5 foot, 5 inches tall and weighs 240 kilos, the typical discount in BMI equates to shedding about 40 kilos.”Obesity impacts virtually one in 5 kids and adolescents worldwide. This power illness is linked with decreased life expectancy and the next threat of creating severe well being issues akin to sort 2 diabetes, coronary heart illness, nonalcoholic fatty liver illness, sleep apnea, and sure cancers. Teenagers with weight problems are additionally extra more likely to have melancholy, anxiousness, poor vanity, and different psychological points.The evaluation confirmed that semaglutide contributors had enhancements in cardiovascular threat elements, together with waist circumference, a blood sugar metric referred to as HbA1c, whole, low-density, and very low-density lipoprotein ldl cholesterol, triglycerides, and liver enzymes in contrast with the placebo group. However, there was no statistically important distinction in blood stress or high-density lipoprotein ldl cholesterol between the 2 teams.Participants who took semaglutide additionally had higher weight-related high quality of life measures, largely resulting from a lift in bodily consolation scores, in contrast with their placebo friends. The researchers word that that is the primary weight problems drug to be linked with such quality-of-life enhancements in adolescents.Reference: “Once-Weekly Semaglutide in Adolescents with Obesity” by Daniel Weghuber, M.D., Timothy Barrett, Ph.D., Margarita Barrientos-Pérez, M.D., Inge Gies, Ph.D., Dan Hesse, Ph.D., Ole Ok. Jeppesen, M.Sc., Aaron S. Kelly, Ph.D., Lucy D. Mastrandrea, M.D., Rasmus Sørrig, Ph.D. and Silva Arslanian, M.D. for the STEP TEENS Investigators, 15 December 2022, New England Journal of Medicine.DOI: 10.1056/NEJMoa2208601The research was funded by Novo Nordisk A/S, the producer of the semaglutide model Wegovy®.


Recommended For You